Patients with BD are three times more likely to be diagnosed with type II diabetes compared to the general population [78], suggesting that NLRP3 inflammasome activation mediated by TXNIP could be underlying increased peripheral and CNS inflammation in patients with BD. The gene discussed is TXNIP; the disease is type 2 diabetes mellitus.